1. Home
  2. HXL vs RNA Comparison

HXL vs RNA Comparison

Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hexcel Corporation

HXL

Hexcel Corporation

HOLD

Current Price

$88.20

Market Cap

6.8B

Sector

Industrials

ML Signal

HOLD

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

HOLD

Current Price

$13.05

Market Cap

226.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXL
RNA
Founded
1946
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
226.3M
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
HXL
RNA
Price
$88.20
$13.05
Analyst Decision
Buy
Buy
Analyst Count
10
20
Target Price
$88.30
$69.26
AVG Volume (30 Days)
845.7K
141.7K
Earning Date
04-22-2026
01-01-0001
Dividend Yield
0.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,893,900,000.00
N/A
Revenue This Year
$10.09
$88.12
Revenue Next Year
$12.33
$18.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.59
$11.95
52 Week High
$98.26
$73.06

Technical Indicators

Market Signals
Indicator
HXL
RNA
Relative Strength Index (RSI) 47.81 38.85
Support Level $80.59 $12.56
Resistance Level $95.16 $13.97
Average True Range (ATR) 2.90 0.45
MACD -0.86 0.25
Stochastic Oscillator 37.96 28.31

Price Performance

Historical Comparison
HXL
RNA

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.

About RNA Avidity Biosciences Inc.

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Share on Social Networks: